文献速递认知障碍与痴呆

儿童起病与成人起病多发性硬化长期认知结局比较

Long-term Cognitive Outcomes in Patients With Pediatric-Onset vs Adult-Onset Multiple Sclerosis.
PubMed 文献 · JAMA Neurol · 2019-01-01

基于瑞典MS注册登记库的纵向队列研究,纳入5704例多发性硬化患者,其中300例为儿童起病。经线性混合效应模型调整后,儿童起病患者SDMT评分显著低于成人起病患者,且下降速度更快,认知障碍风险更高。

要点

  • 儿童起病多发性硬化患者SDMT评分较成人起病患者低3.59分(95%CI -5.56至-1.54)。
  • 儿童起病患者SDMT评分下降速度更快(β=-0.30,95%CI -0.42至-0.17)。
  • 儿童起病患者认知障碍风险显著升高(OR=1.44,95%CI 1.06-1.98)。

核心结论

  • 儿童起病多发性硬化患者成年后信息处理效率下降更快,认知障碍风险更高,且独立于年龄或病程。

研究设计与样本

  • 基于瑞典MS注册登记库的纵向队列研究,纳入5704例多发性硬化患者,其中300例(5.3%)为儿童起病。

主要发现

  • 调整性别、年龄、病程、疾病病程类型、SDMT完成总次数、SDMT形式及DMT暴露后,儿童起病患者SDMT评分显著低于成人起病患者(β=-3.59,95%CI -5.56至-1.54)。
  • 儿童起病患者SDMT评分下降速度显著快于成人起病患者(β=-0.30,95%CI -0.42至-0.17)。
  • 儿童起病患者认知障碍的比值比显著升高(OR=1.44,95%CI 1.06-1.98)。

临床怎么用

  • 对儿童起病多发性硬化患者应关注长期认知功能监测,尤其是信息处理效率。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Cognitive impairment in multiple sclerosis (MS) can lead to reduced quality of life, social functioning, and employment. Few studies have investigated cognitive outcomes among patients with pediatric-onset MS (POMS) over the long term. OBJECTIVE: To compare long-term information-processing efficiency between patients with POMS and adult-onset MS (AOMS). DESIGN, SETTING, AND PARTICIPANTS: This population-based longitudinal cohort study accessed the Swedish MS Registry (SMSreg), which collates information from all 64 neurology clinics in Sweden. Registered cases with definite MS in the SMSreg with an onset before April 15, 2018, and at least 2 Symbol Digit Modalities Test (SDMT) scores recorded were included. Only persons aged 18 to 55 years and with duration of disease of less than 30 years at the time of SDMT administration were included, to ensure comparable ranges between patients with POMS and AOMS. Of 8247 persons with an SDMT recorded in the SMSreg, 5704 met inclusion criteria, 300 (5.3%) of whom had POMS. Data were collected from April 1, 2006, through April 15, 2018 and analyzed from April through August 2018. EXPOSURES: Pediatric-onset MS (onset <18 years of age) vs AOMS (onset ≥18 years of age). MAIN OUTCOMES AND MEASURES: Information-processing efficiency measured every 6 or 12 months by the SDMT. Linear mixed-effects models were used to compare all available SDMT scores between patients with POMS and those with AOMS. Persons with cognitive impairment (ever vs never) were identified using regression-based norms and compared between POMS and AOMS groups using logistic regression. RESULTS: Of the 5704 participants, 4015 were female (70.4%), and 5569 had a relapsing-onset disease course (97.6%). Most participants were exposed to a disease-modifying therapy (DMT) during follow-up (98.8%). Median age at baseline for the POMS group was 25.6 years (interquartile range, 21.0-31.7 years) and for the AOMS group, 38.3 years (interquartile range, 31.4-45.2 years). A total of 46 429 unique SDMT scores were analyzed. After adjustment for sex, age, disease duration, disease course, total number of SDMTs completed, oral or visual SDMT form, and DMT exposure, the SDMT score for patients with POMS was significantly lower than that of patients with AOMS (β coefficient, -3.59 [95% CI, -5.56 to -1.54]). The SDMT score for patients with POMS declined faster than that of patients with AOMS (β coefficient, -0.30 [95% CI, -0.42 tp -0.17]). The odds of cognitive impairment were also significantly elevated in the POMS group (odds ratio, 1.44; 95% CI, 1.06-1.98). CONCLUSIONS AND RELEVANCE: In adulthood, patients with POMS demonstrated a more rapid reduction in information-processing efficiency over time and were more likely to experience cognitive impairment than patients with AOMS, independent of age or disease duration. Further investigation is required to understand the mechanisms by which early MS onset influences cognitive outcomes.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. McKay KA, Manouchehrinia A, Berrigan L, et al. Long-term Cognitive Outcomes in Patients With Pediatric-Onset vs Adult-Onset Multiple Sclerosis. JAMA Neurol. 2019. PMID: 31206130. doi:10.1001/jamaneurol.2019.1546

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。